BrainsWay to Participate in Virtual Conferences Elevate by Psych Congress Virtual Experience and Online Obsessive-Compulsive ...
21 July 2020 - 11:00PM
BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the
“Company”), a global leader in the advanced noninvasive treatment
of brain disorders, today announced the Company will participate in
the upcoming mental health conferences:
- Elevate by Psych Congress Virtual Experience through July 25
-27. The conference brings together global mental health
organizations and industry leaders, presenting a unique chance for
professionals around the country to connect on the latest
innovations and therapy development, research and more.
- Online OCD Conference through July 31 - August 2. The first
event of its kind, the conference encourages attendance from all
members within the OCD community, including individuals with lived
experience, their family members and supporters, and the
professionals who treat them.
“It is an honor to connect with and hear from each of the
communities represented at Elevate by Psych Congress and at the
Online OCD Conference. Those attending directly impact our mission
of fostering innovative treatment and, ultimately, hope around
mental health conditions,” said Christopher von Jako, Ph.D.,
President and CEO of BrainsWay. “We also look forward to using this
opportunity to raise awareness and spark conversations around
noninvasive treatment options such as Deep Transcranial Magnetic
Stimulation, also known as Deep TMS.”
BrainsWay is committed to raising awareness and providing
education around mental health, specifically for those with major
depressive disorder and obsessive-compulsive disorder (OCD), for
which Deep Transcranial Magnetic Stimulation (Deep TMS) is FDA
cleared. Deep TMS is a noninvasive treatment administered using
BrainsWay’s proprietary H-coil which is used to transmit
electromagnetic pulses in order to stimulate the regions of the
brain associated with various mental health conditions. The coil is
encased in a cushioned helmet that is placed over the patient’s
head during therapy. The treatment is medication-free, and
patients can return to normal activities, such as driving,
immediately following treatment.
About BrainsWay
BrainsWay is a commercial-stage medical device
company focused on the development and sale of non-invasive
neuromodulation products using the Company’s proprietary Deep
Transcranial Magnetic Stimulation (Deep TMS) technology for the
treatment of major depressive disorder (MDD) and
obsessive-compulsive disorder (OCD), for which BrainsWay received
marketing authorization from the U.S. Food and Drug Administration
(FDA) in 2013 for MDD and in 2018 for OCD. BrainsWay is currently
conducting clinical trials of Deep TMS in other psychiatric,
neurological, and addiction disorders. Any forward-looking
statements are subject to risks and uncertainties such as those
described in BrainsWay's periodic reports on file with the
Securities and Exchange Commission. Actual results may differ
materially from anticipated results.
Contacts: BrainsWayJudy HuberSVP and
Chief Financial Officer Judy.huber@brainsway.com
Media:Holly Dugan(201) 465-8019Brainsway@antennagroup.com
Brainsway (NASDAQ:BWAY)
Historical Stock Chart
From Apr 2024 to May 2024
Brainsway (NASDAQ:BWAY)
Historical Stock Chart
From May 2023 to May 2024